Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | GPR4 | P46093 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569650 | 0.86 | RORC (0.37) | RORCBACE1CTSDCTSEHDAC1 | |
| SCHEMBL10255921 | 0.86 | RORC (0.37) | RORCBACE1CTSDCTSEHDAC1 | |
| SCHEMBL569649 | 0.86 | RORC (0.37) | RORCBACE1CTSDCTSEHDAC1 | |
| SCHEMBL20341701 | 0.85 | RORC (0.40) | RORCBACE1CTSDCTSEHDAC1 | |
| SCHEMBL18587858 | 0.83 | RORC (0.40) | RORCBACE1CTSDCTSENR1H2 | |
| SCHEMBL569652 | 0.83 | RORC (0.54) | RORCBACE1CTSDCTSE | |
| SCHEMBL15223009 | 0.83 | RORC (0.50) | RORCGPR119 | |
| SCHEMBL15155806 | 0.82 | GPR119 (0.50) | RORCBACE1CTSDCTSEGPR119 | |
| SCHEMBL17729554 | 0.82 | MAPT (0.51) | RORCGPR119 | |
| SCHEMBL15532821 | 0.81 | GPR119 (0.51) | RORCBACE1CTSDCTSENR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9073912-B2 | Azetidine derivatives as antiparasitic agents | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073912-B2 | Azetidine derivatives as antiparasitic agents | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073912-B2 | Azetidine derivatives as antiparasitic agents | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150119377-A1 | AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150119377-A1 | AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150119377-A1 | AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2015-04-30 | — | — | US | disclosed |
| EP-2855457-A1 | AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | Zoetis Products LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013169622-A1 | AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2601190-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | AH USA 42 LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | RORC 519/4885BACE1 3596/4885CTSD 2661/4885 |
| US-20150119377-A1 | AZETIDINE DERIVATIVES AS ANTIPARASITIC AGENTS | CYP1B1, ADORA1, QDPR | RORC 1226/4885BACE1 4110/4885CTSD 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.